Clinico-epidemiologic features of granuloma inguinale in the era of acquired immune deficiency syndrome.
OBJECTIVE
Granuloma Inguinale (GI) is an endemic sexually transmitted disease (STD) in India. With increasing prevalence of human immunodeficiency virus (HIV) among patients with STD at a clinic in Mumbai, a study was conducted to determine clinico-epidemiologic features of GI and HIV.


OBJECTIVE
To determine possible interaction between GI and HIV.


METHODS
Prospective follow-up of 21 consecutive cases (GI in HIV-seropositive individuals) and 29 controls (GI in HIV-seronegative individuals) to determine time to heal. All cases and controls received a standard treatment regimen of erythromycin, 2 g po daily, under supervision until healing occurred.


RESULTS
Although GI ulcers at recruitment were not significantly larger among HIV-seropositive individuals as compared with those seen among HIV-seronegative individuals (mean size 4.4 cm2 vs. 3.6 sq2; odds ratio [OR] 1.22, confidence interval [CI] .95, 0.63, 2.40; p = 0.52), the former took longer time to heal completely (mean 25.7 days vs. 16.8 days; OR 1.82, CI .95, 0.99, 3.36; p = 0.03) and tended to produce greater tissue destruction (as included in results).


CONCLUSIONS
These findings are important because slow-healing GI ulcers with underlying HIV infection, which may be caused by their interaction, will lead to increased transmission of both the infections.
Jamkhedkar
P P
PP
Department of Skin/STD, Sir J. J. Hospital, Mumbai, India.
Hira
S K
SK
Shroff
H J
HJ
Lanjewar
D N
DN
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000453:epidemiology*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006100:Granuloma Inguinale / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D015528:HIV Seroprevalence; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D012074:Remission Induction
D000900:Anti-Bacterial Agents; D004917:Erythromycin